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In the post-genomic era, genetics has gradually begun to assume a central role in 
modern medical practice. However, in many European countries, very little is currently 
known regarding the level of awareness of healthcare professionals with respect to 
pharmacogenomics and personalized medicine. We have previously conducted a pilot 
nationwide survey to assess how the general public and physicians in Greece perceive 
genetics. Here, we report our the findings from of a more in-depth study, involving 
healthcare professionals, namely 86 pharmacists and 208 physicians, to assess their level of 
awareness of pharmacogenomics and personalized medicine. Our findings indicate that a 
substantial number of pharmacists (around 60%) consider their level of knowledge of 
personalized medicine to be very low, while with around 80% of the pharmacists and 58% 
of physicians indicated intimating that they would be unable to provide sufficient 
information or explain the results of pharmacogenomic tests to their customers or patients, 
respectively. This situation is may be directly related to the low level of their undergraduate 
education in genetics and pharmacogenomics, as indicated by the an assessment of the 
pharmacists’ knowledge of basic genetics knowledge. Further, our surveys revealed that 
physicians are more frequently often involved with genetics and pharmacogenomics in 
their routine practice than pharmacists, and have more frequently advised their patients to 
undergo genetic and/or pharmacogenomic testing. Interestingly, although only 7% of the 
pharmacists provide sample collection kits for downstream genetic analysis over the 
counter, a much larger proportion, i.e. (30%), are in favor of direct-to-consumer genetic 
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testing in principle. Overall, a large proportion of healthcare professionals are of the 
opinion that, in relation to personalized medicine in Greece, a well-regulated environment 
and legal framework are conspicuous by their absence. These findings provide the basis for 
an improved assessment of the views of healthcare professionals in relation to personalized 
medicine in Greece. It is to be hoped that this survey will not only improve, but also and 
expedite, the integration of genomics into the current medical decision-making process in 
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Personalized or genomic medicine exploits genomic information not only in the 
context of rationalizing drug use prescription but also by influencing the overall medical 
decision-making process to the benefit of both the patient and the national healthcare 
system. Analysis of an individual’s or a family’s whole genome sequence(s) would, in 
principle at least, enable physicians to make assessments of disease risk, determine an 
individual’s pharmacogenomic profiles and, hence, arrive at decisions regarding treatment 
modalities [1,2]. In recent years, personalized healthcare has become a reality by 
combining whole-genome information with a patient’s clinical profile [3]. As a result, not 
only can preventive medicine strategies be optimized but also conventional therapeutic 
interventions can also be individualized. The latter constitutes a major challenge for 
customizing patient care [4].  
Unfortunately, the level of public awareness of genetics and its impact to upon 
society is often rather low, and the same is true for healthcare professionals who are 
supposed to be in the front-line of delivering these services to the general public. The lack 
of genetics awareness among healthcare professionals constitutes a major barrier to 
expediting the implementation of genomic medicine with its potential to adjust 
conventional treatment modalities according to a patient’s genomic profile. This situation 
results inis exacerbated by a poorly developed and regulated genetic testing landscape in 
many European countries, as indicated by the paucity of the literature on this topic both in 
European countries and the United States [5-7]. Thus, determining the level of awareness 
of the general public and healthcare professionals with respect to genetics and genomic 
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medicine and their potential benefits to society, together with the challenges and pitfalls 
that need to be overcome, has become a major goal. For this reason, we have initiated 
nationwide surveys in Greece to critically ascertain patients’ and healthcare professionals’ 
views about genetics, pharmacogenomics and personalized medicine.  
We have previously reported our results from a nationwide survey to study the attitudes 
and views of the private genetic testing laboratories in Greece [8]. We have also performed 
pilot surveys of the views of the general public and physicians in Greece, with the aim of 
understanding both the wishes and needs of patients and physicians in relation to genetics 
and genetic testing and to identify regulatory deficiencies and gaps in the existing legal 
provision [9,10]. 
Here, we report our findings from a thorough survey of healthcare professionals, 
specifically physicians and pharmacists, to ascertain their opinion of various issues 
pertaining to genetics, personalized medicine and its their impact on society. This study 
provides useful insights and which can we hope will be potentially replicated in other 
European countries, with the aiming to of engaginge healthcare providers more actively in 
all aspects of genomic medicine., Thiswhich will in turn facilitate the incorporation of 




A cross-sectional survey design was used for this study which was conducted 
between June 2010 and September 2012. We formulated two independent questionnaires 
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(see Supplementary information) from which the data on individual perceptions of 
genetics, pharmacogenomics and personalized medicine were generated. We provided the 
necessary clarifications to questions posed by the survey respondents when required to do 
so, in order to ensure that a valid response was given to each question.  
In both questionnaires, non-random sampling was employed. One hundred and 
thirty seven pharmacists, selected from three cities mainly in Western Greece, were 
personally interviewed, using a questionnaire that was divided into four sections: (a) the 
first section (questions 1-5) requested demographic information such as age, gender and 
place and level of studies (BSc, MSc/PhD), (b) the second section (questions 6-7) aimed 
to assess their professional experience, (c) the third section (questions 8-15) aimed to 
assess the genetics knowledge of the respondents, and (d) the fourth section (questions 
16-35) posed 20 questions regarding various aspects of genetics, such as awareness of and 
personal opinions about genetics, genetic tests and the use of pharmacogenomic testing 
from health care providers.  
A similar questionnaire was distributed to 208 physicians from all medical 
specialties who attended the national (Greek) medical conference in May 2011 and May 
2012, to ensure a broad coverage of physicians from all specialties and from all 
geographical regions within Greece, and contained the following sections: (a) the first 
section (questions 1-5) requested demographic information such as age, gender, place and 
level of studies (MD, MSc/PhD) and specialty, (b) the second section (questions 6-8) 
aimed to assess their professional experience, and (c) the third section (questions 9-23) 
contained 15 questions regarding various aspects of genetics, such as awareness of and 
 7 
personal opinions about genetics, genetic tests and the use of pharmacogenomic testing 
from health care providers. Ten questions were identical between the questionnaires for 
the sake of comparison (Supplementary information). 
 
Measures 
The questionnaires provided prospective data for this analysis. The dependent 
variables were derived from the questions in both questionnaires, scored using either a 
binary model (0=No, 1=Yes), or the Likert-type scale (1-5). Independent variables 
comprised the demographic characteristics of respondents, specifically their age, gender, 




All statistical analyses were performed using the Statistical Package for the Social 
Sciences, version 18.0 (SPSS Inc., Chicago, IL, USA) and the chi-square test. We also 
checked the data for completeness and frequency distributions. Mean values, standard 
deviations, and percentages were computed to describe the distribution of independent 
variables. Cross-tabulation tables (contingency tables) were created to display the 
relationship between two or more (nominal or ordinal) variables using the chi-square test. 





The overall sample sizes and characteristics of the surveyed pharmacists and 
physicians groups are shown in Table 1. Every effort was made in the context of both the 
general public [GEORGE: Do you mean the pharmacists?] and the physicians’ groups to be 
as representative as possible regarding age and gender.  
Figure 1A depicts the most common medical specialties of those physicians who 
responded to our survey. A full list of these medical specialties is provided in the 
Supplementary information. Figure 1B depicts the pharmacists’ professional experience, 
from which it can be seen that almost 60% of the pharmacists who participated in this 
survey had practiced pharmacy for more than 10 years, with the vast majority (84/86; 
97.7%) of them either being employed in, or owning, a private pharmacy.   
The opinions of the physicians and pharmacists were assessed with respect to the 
following three issues: (a) level of awareness of genetics and pharmacogenomics, (b) 
involvement with genetics, genetic testing and pharmacogenomics, and (c) professional 
opinions regarding ethical, legal, societal and regulatory issues pertaining to genetics and 
pharmacogenomics. The pharmacists were also interviewed to assess their basic knowledge 
of genetics, since their formal genetics education is often very limited. 
 
Awareness over of genetics and pharmacogenomics 
We first attempted to assess the level of awareness of healthcare professionals of 
genetics and pharmacogenomics. Around 60% of the pharmacists interviewed admitted that 
their level of genetics knowledge wais very low, while an almost equal number of 
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pharmacists [GEORGE: percentage?] professed awareness of pharmacogenomics and its 
relationship with personalized medicine (Fig. 2). Some 58% of the pharmacists felt that 
they knew very little or nothing or had very poor knowledge ofabout genetics (Q16B), and 
pharmacogenomics and personalized medicine (Q17B), while a mere 4.6% felt that their 
knowledge level of genetics, pharmacogenomics and personalized medicine was high or 
very high (Figs. 2A, B). Almost 45% of physicians admitted volunteered that their 
knowledge level of pharmacogenomics and personalized medicine (Q12A) was poor or 
very poor, while around 24% of respondents felt that their knowledge level of genetics, 
pharmacogenomics and personalized medicine was high or very high (Fig. 2C). A similar 
response pattern was also observed in physicians and pharmacists with regard toing 
self-assessment of the undergraduate level of their education in genetics and 
pharmacogenomics (Q20A and Q20B, respectively; Fig. 2D). Finally, approximately 78% 
of the physicians and 58% of pharmacists would be interested in attending educational 
events in relation to genetics and pharmacogenomics (Supplementary information), 
indicating their willingness, at least in principle, to improve their knowledge of this 
emerging field in medicine. 
Genetic and pharmacogenomic tests are gradually becoming integrated into the 
modern medical decision-making process. Indeed, there are an increasing number of 
genetic tests that are being made available worldwide from genetic laboratories, but also 
directly to the consumer via the internet, or (even more recently) over the counter in 
pharmacies. We asked the pharmacist’s group whether they provide genetic analysis kits 
(e.g. buccal swabs or saliva collection kits) over the counter. Our data The responses given 
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show indicated that only 7% of the pharmacists provide such genetic analysis kits over the 
counter, while almost 9 out of 10 pharmacies do not (Q22B; Fig. 3A). Interestingly, aA 
significantly larger proportion of pharmacists, i.e. (45%), were aware that genetic analysis 
kits are considered to be a medical devices and as such they require regulatory clearance to 
be sold over the counter in pharmacies (Q23B). However, a smaller proportion (31%) were 
aware that certain drug labels specify that it is recommended to undertake a 
pharmacogenomic test prior to obtaining the drug in question so as to avoid an adverse drug 
reaction (Q26B; Fig. 3A). 
It is broadly accepted that pharmacogenomics contributes towards a reduction not 
only in healthcare costs by minimizing adverse drug reactions, but also in the overall cost of 
developing new drugs by stratifying patients’ subgroups in clinical trials. Therefore, we 
posed these questions to pharmacists in order to ascertain whether they are familiar with 
these issues. We found that around 60% of the respondentsing pharmacists believed that 
pharmacogenomics can help to reduceing the occurrence, overall frequency and severity of 
adverse drug reactions (Q31B), while 65% believed that pharmacogenomics can help to 
reduce healthcare costs by rationalizing drug use (Q33B; Fig. 3B). However, only one third 
of the responding pharmacists believed that pharmacogenomics would play a role in 
reducing the cost of developing new drugs (Q32B; Fig. 3B).  
 
Involvement with genetics, genetic testing and pharmacogenomics 
Subsequently, we addressed the level of involvement of physicians and pharmacists 
with genetics, genetic testing services and pharmacogenomics. Firstly, we asked physicians 
Formatted: Font: Not Italic
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and pharmacists about the extent to which pharmacogenomics and pharmacogenomic 
testing were involved in their daily practice. From their responses, we surmise that 
physicians are more frequently involved with genetics and pharmacogenomics in their 
routine practice than pharmacists. However, more than half of the respondentsm stated that 
their level of involvement wais low, with 53% of physicians and 73% of pharmacists being 
only rarely becoming involved with pharmacogenomics (Fig. 4A).  
When we assessingenquired whether physicians hadve advised their patients to 
undergo genetic and/or pharmacogenomic testing, more than half (i.e., 53%) stated that 
they have advised their patients to do so. By contrast, a mere 15% of the pharmacists stated 
that they hadve advised their clients to undergo genetic and/or pharmacogenomic testing 
(Fig. 4B). The same pattern was also observed when physicians and pharmacists were 
asked whether their patients had sought their advice in relation to undertaking genetic 
and/or pharmacogenomic testing (42% vs. 9%, respectively; Fig. 4B). At the same time, 
79% of the pharmacists indicated that they could not provide sufficient information to their 
clients or explain the results of pharmacogenomic tests to them (Q27B);, while this 
percentage was much lower in the physicians group (58%; Q16A: Fig. 4C). 
 
Professional opinions on ethical, legal, societal and regulatory issues pertaining to 
genetics and pharmacogenomics 
Genetic analysis must always comply with various ethical, legal, societal and 
regulatory guidelines. As such, we sought the opinion of our groups of healthcare 
professionals on this important mattertopic.  
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A large proportion of healthcare professionals (69% of physicians and 77% of 
pharmacists) believe that in Greece there is currently neither a well-regulated environment 
nor the appropriate legal framework to covering genetic and pharmacogenomic testing to 
protect the general public and ensure privacy, informed consent, control of the costs of 
genetic analysis, monitoring of the accreditation of genetic laboratories, etc; Fig. 5A). In 
particular, 72% of the pharmacists thought that pharmacogenomic information could 
potentially be maliciously exploited by employers and insurance companies in order to 
discriminate against certain patients or population subgroups (not shown).  
An even bigger proportion, namely 86% of physicians and 66% of pharmacists 
disagreed with the idea of direct-to-consumer genetic testing (Fig. 5B), while 62% of 
physicians and 66% of pharmacists believed that the cost of pharmacogenomic testing 
should be covered by insurance companies (Fig. 5C). Overall, the majority of healthcare 
professionals (50% of physicians and 70% of pharmacists) agreed that the results of 
pharmacogenomic testing would have a positive impact only affect patient medical care for 
the patients by rationalizing their drug prescription and dosage, their frequency of medical 
appointments and overall diagnoses (Fig. 5D).  
 
Assessing genetics knowledge among pharmacists 
Finally, we wished to assess how well educated pharmacists are in relation to genetics 
and pharmacogenomics. Our data revealed that the younger pharmacists and those with a 
graduate degree (MSc and/or PhD) are better informed about genetics as compared to the 
older generation of pharmacists and those who have not studied at postgraduate level. Thus, 
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77% of the younger pharmacists (<35 yr old) correctly stated that the DNA is 99% identical 
among between different individuals compared to 44% of the older pharmacists (>35 yr 
old; Q8B; p<0.001). AlsoIn addition, 8 out of 10 pharmacists correctly statedrealised that 
the statement “... adenine only pairs with cytosine and thymine only pairs with guanine” 
(Q10B) was wrong, while 6 out of 10 pharmacists correctly statednoticed that the statement 
“Humans have 48 chromosomes” (Q9B) was wrong. In both cases, pharmacists with a 
post-graduate education gave tended to give more correct answers (p<0.001). All of the 
younger pharmacists (<35 yr old) correctly stated that DNA changes are capable of 
influencing drug response compared to just 82% of the older pharmacists (Q13B; p=0.015), 
while 97% of the younger pharmacists opined that DNA changes could result in adverse 
drug reactions as compared to almost 62% of the older pharmacists (Q14B; p<0.001). 
Further, 71% of younger pharmacists were of the opinion that pharmacogenomic analysis is 
not appropriate for all drugs, while this percentage is lower for older pharmacists (Q15B; 
p=0.042). When we assessed the influence of post-graduate education on genetics 
knowledge, we found that pharmacists with a graduate title (MSc and/or PhD) have a better 
genetics education compared to those that who have not followed post-graduate studies (not 
shown). These data are summarized in Figure 6. 
    
Discussion 
 In recent years, it has become clear that pharmacogenomics has the potential to 
ensure optimal treatment and medication use in a growing number of diseases. The advent 
of high-throughput genotyping and whole-genome sequencing analysis has revolutionized 
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medical practice bringing the notion concept of personalized genomic medicine ever 
closer to reality, and resultinged in a steady increase in the number of genetic tests 
becoming available, a number which is expected to increase steadily in the years to come 
[11].  
Given the potential of genomic medicine to grow exponentially, it is imperative that 
comprehensive analyses are performed in various countries to assess the level of 
awareness of healthcare professionals in relation to genomics and personalized medicine 
to expediteso that the delivery of genomic services may be expedited in their respective 
healthcare systems. Genetics education and communication will also play an important 
role in increasing the level of awareness of the general public with respect to genomic 
medicine so that they come to appreciate the benefits that this new discipline can offer 
[12].   
There are currently very few studies that have attempted to fine map the differences 
between individual countries regarding the level of education and awareness of healthcare 
professionals in relation to pharmacogenomics and genomic medicine. In contrast to the 
United States, significant differences have been documented between individual European 
countries, even between European Union member states [5-9], and in-depth analysis, 
based upon comprehensive surveys is still lacking. We have previously attempted to 
explore how both the general public and medical practitioners perceive genetics and 
genetic testing services in Greece [8,9] and to correlate this information with the existing 
private genetic testing environment in Greece [10]. For the first time in Europe, tThese 
surveys paid, for the first time in Europe, special attention to attitudes to 
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This study has attempted to shed new light into the ways that healthcare 
professionals perceive genomic medicine, and pharmacogenomics in particular. This 
study differs significantly from that recently conducted in Greece [8] in the following 
reaspects: (a) this study comparatively evaluated the views of physicians and pharmacists 
in relation to key aspects of genomic medicine, (b) both questionnaires were designed 
(using the Likert scale) in such a way as to allow better analysis of the responses of the 
target groups, (c) this study attempted to correlate genomic knowledge with professional 
and training experience, and (d) this study has highlighted the willingness of both target 
groups to participate in continuous educational events over pharmacogenomics. 
As with our previous study, we opted to carry out personal interviews rather than 
acquire information by means of impersonal electronic surveys since it not only allowed 
us to provide clarification to the respondents when required to do so. The latter could also 
have introduced bias since theose most computer literate individuals who are most 
computer literate are also likely to be the best informed about genetic testing. Pharmacists 
were approached in their practice, whereas physicians were selected while attending two 
major annual national medical conferences in Athens. However, contrary in comparison 
to our previous study, we have significantly expanded the questionnaires, since we sought 
a more detailed evaluation of the views of our target groups.  
 
Perception of genomic medicine and pharmacogenomics 
Integration of genomic information into the mainstream medical decision-making 
process depends upon several parameters. Increased awareness of various aspects of 
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genomic medicine greatly facilitates the entire process. Our results indicate that 
approximately 60% of the pharmacists who responded to our survey admitted 
thatconsidered their level of genetics knowledge was to be low, a proportion comparable 
to the pharmacists who admitted very limited or no knowledge of pharmacogenomics and 
its relationship with personalized medicine (Fig. 2). Only 4.6% of pharmacists felt that 
their genetics and pharmacogenomics knowledge was high. This situation contrasts with 
that for the physicians as a group; the percentage proportion of the physicians who 
admitted their level of knowledge level ofver pharmacogenomics and personalized 
medicine was poor or very poor was significantly lower (45%), while 24% of the 
physicians felt that their level of knowledge of genetics, pharmacogenomics and 
personalized medicine was high or very high (Fig. 2C; p<0.05). This difference can most 
likely easily be explained by the fact that genetics and molecular biology courses are 
included for a longer period of time in the medical schools in Greece compared to the 
schools of pharmacy. It is unfortunate that in the latter schools in Greece, the 
undergraduate curricula only touch uponaddress these topics quite superficially. When 
physicians and pharmacists were asked to self-assess the level of their undergraduate 
education with respect to genetics and pharmacogenomics, similar responses were given 
(Fig. 2D).  
The educational level of the physicians and pharmacists with respect to genetics and 
pharmacogenomics could also be defined in relation to their level of involvement with 
genetic and pharmacogenomic testing services. Our results show that although physicians 
are more frequently involved with genetics and pharmacogenomics in their routine practice 
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as compared to pharmacists, more than half of them indicated that the level of their 
involvement with pharmacogenomics was low (53% of physicians vs. 73% of pharmacists). 
Moreover, significantly more physicians (53%) have advised their patients to undergo 
genetic and/or pharmacogenomic testing, compared to 15% of pharmacists (15%; Fig. 4B). 
Aand a comparable trend was also observed when physicians and pharmacists were asked 
whether their patients had enquired about undertaking genetic and/or pharmacogenomic 
testing (42% vs. 9%, respectively; Fig. 4B). These data are comparable with our previous 
survey [48%; 8].  
Interestingly, a large proportion of pharmacists (79%) felt that that they could not 
provide sufficient information or explain the results of pharmacogenomic tests to 
customers, while only 5% stated that they could satisfactorily explain the results of 
pharmacogenomic tests, a response which is directly proportional to their genetics 
education. This result is similar to a recent study performed in a Canadian pharmacist 
respondent group, only 7.7% of whom felt comfortable advising patients and interpreting 
their pharmacogenomic test results [15]. As previously indicated, the proportion of 
physicians stating that they were unable to explain genetic and pharmacogenomic test 
results was much lower than the pharmacists while reciprocally the proportion of 
physicians who stated that they were in a position to adequately interpret genetic test results 
was significantly higher than the pharmacists (58% and 15%; p<0.01). 
In recent years, kits for sample collection for downstream genetic tests have become 
widely available over the counter in pharmacies. Our group of pharmacists indicated that 
only 7% of them sell such kits over the counter, whereasilst almost 9 out of 10 pharmacies 
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do not. Such collection kits are considered medical devices and as such, special clearance is 
required from regulatory agencies to sell them. Interestingly, only 45% of the pharmacists 
that who responded to our survey were aware that the genetic analysis kits are considered 
medical devices. Surprisingly, 8% and 22% of pharmacists agreed or somewhat agreed 
with the notion idea of direct-to-consumer genetic and pharmacogenomic testing, 
compared to 5% and 9% of physicians, respectively. Although the results from the 
physicians group were in full agreement with our previous surveys [8,9], the smaller 
proportion of the pharmacists who were opposed to direct-to-consumer (DTC) genetic and 
pharmacogenomic testing is of special interest, warranting further investigation, and could 
be partly explained by the limited information available to this professional group 
regarding the risks of DTC genetic testing. The issue of DTC genetic testing is a 
controversial one and there are considerable differences in the regulatory framework 
between the US and Europe [16]. AlsoMoreover, considering the absolute need for a doctor 
to mediate between the patient and the diagnostics company offering the pharmacogenomic 
test, extra caution should be exercised with DTC pharmacogenomic testing [17], 
particularly those sold overn the Internet, since a large number of themproportion may be 
indeed inaccurate or even completely useless. It is truly unfortunate that there are somefew 
Greek companies that are offering pharmacogenomic tests using the DTC model, some of 
them via the Internet [GEORGE: Is this what you want to say. You were actually saying the 
opposite!]. This discrepancy is also indicative a symptom of the lack of a well-regulated 
testing with the aim of protecting the general public and ensuring privacy, consented 
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analysis, control of genetic analysis costs, monitoring genetic laboratories accreditation, a 
point made by both respondent groups (Fig. 5).   
It is broadly accepted that pharmacogenomics has the potential to improve quality of 
life at the same time as reducing healthcare costs by minimizing adverse drug reactions at 
both a personal and national level. Around 60% of the responding pharmacists believed that 
pharmacogenomics can has the potential to help to reduce the incidence and severity of 
adverse drug reactions, while 65% believed that pharmacogenomics can contribute towards 
reducing healthcare costs by rationalizing drug use. At the same time, 62% of physicians 
and 66% of pharmacists believe that the cost of pharmacogenomic tests should be covered 
by insurance companies.  Surprisingly, only 31% of the respondent pharmacists were 
aware that certain drug labels indicate that a pharmacogenomic test should be undertaken 
prior to obtaining or being prescribed the drug in order to avoid adverse drug reactions. 
Overall, the majority of healthcare professionals (50% in the physicians group and 
70% in the pharmacists group) agree that the results of pharmacogenomic testing will 
positively affect medical care for the patients by rationalizing their drug type and dose, their 
frequency of medical appointments and overall diagnoses. 
 
Knowledge and education of pharmacists in relation to pharmacogenomics 
In several countries, pharmacists are considered to be experts in medication and as 
such, they are expected to be able to use pharmacogenomic information appropriately in 
order to individualize treatment regimens. Pharmacists can be particularly useful in the 
implementation of pharmacogenomics, mainly by assisting clinicians to ensure that all 
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available pharmacogenomic information is considered in the medical decision-making 
process, or by acting as educators for to patients and healthcare professionals to in the 
context of raisinge awareness of pharmacogenomics. As such, pharmacogenomics should 
have an integral part in modern undergraduate curricula in schools of medicineal and 
pharmacy schools. Our findings suggest that younger pharmacists and those with graduate 
degrees, despite having less professional experience, are likely to have a better 
understanding of genetics and pharmacogenomics (Fig. 6). This could be because genetics 
and molecular biology have only recently been added to the undergraduate pharmacy 
curriculum. These findings also concur with those findings of a recent survey of 284 
pharmacists practicing in the province of Québec (Canada) with more than 95% of 
respondentsrs willing to recommend pharmacogenomic testing, and 97% of respondentsrs 
indicating that they would like to undertake continuing education related to 
pharmacogenomics [15]. This latter proportion was much higher than in our own survey 
(58% for pharmacists and 78% for physicians, respectively).  
 It should be noted that, in our own study, 51 pharmacists who were approached 
refused to participate in the survey (37%); 14 of these were unaware of the term 
pharmacogenomics. It is also noteworthy that 6 of the pharmacists [GEORGE: who 
declined to take part?] stated that this survey was insulting, maintaining that pharmacists 
should not participate in this type of survey, while 12 pharmacists gave other excuses for 
not participating. Taken together, these findings indicate that although most pharmacists 
have a positive view  of pharmacogenomics and are willing to increase their knowledge of 
pharmacogenomics with a view to gradually integrating it into their clinical practice, good 
 21 




We are indebted to the participants of our surveys without whose cooperation, this 
study would not have been possible. This work was endorsed by the Genomic Medicine 
Alliance and partly funded by the Golden Helix Institute of Biomedical Research and by a 
European Commission grant (FP7-305444) to GPP.  
 
References 
1. Chen JM, Férec C, Cooper DN. Revealing the human mutome. Clin. Genet. 78(4): 
310-320 (2010). 
2. Cooper DN, Chen JM, Ball EV et al.: Genes, mutations, and human inherited disease 
at the dawn of the age of personalized genomics. Hum. Mutat. 31(6), 631-655 (2010). 
3. Guttmacher AE, McGuire AL, Ponder B, Stefánsson K. Personalized genomic 
information: preparing for the future of genetic medicine. Nat. Rev. Genet. 
11(2):161-165 (2010).  
4. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and 
applications. Transl. Res. 154(6):277-287 (2009).  
5. Hietala M, Hakonen A, Aro AR, Niemelä P, Peltonen L, Aula P. Attitudes toward 
genetic testing among the general population and relatives of patients with a severe 
genetic disease: a survey from Finland. Am. J. Hum. Genet. 56(6):1493-1500 (1995). 
 22 
6. Balck F, Berth H, Meyer W. Attitudes toward genetic testing in a German population. 
Genet. Test. Mol. Biomarkers 13(6):743-750 (2009). 
7. Makeeva OA, Markova VV, Roses AD, Puzyrev VP. An epidemiologic-based survey 
of public attitudes towards predictive genetic testing in Russia. Per. Med. 7(3): 
291-300 (2010). 
8. Mai Y, Koromila K, Sagia A et al. A critical view of the general public’s awareness 
and physicians’ opinion of the trends and potential pitfalls of genetic testing in 
Greece. Per. Med. 8(5):551-561 (2011). 
9. Pavlidis C, Karamitri A, Barakou A, Cooper DN, Poulas K, Topouzis S, Patrinos GP. 
Ascertainment and critical assessment of the views of the general public and 
healthcare professionals on nutrigenomics in Greece, Per. Med. 9(2): 201-210 (2012). 
10. Sagia A, Cooper DN, Poulas K, Stathakopoulos V, Patrinos GP. A critical appraisal 
of the private genetic and pharmacogenomic testing environment in Greece. Per. 
Med. 8(4):413-420 (2011). 
11. Metzker ML. Sequencing technologies - the next generation. Nat. Rev. Genet. 
11(1):31-46 (2010). 
12. Reydon TA, Kampourakis K, Patrinos GP. Genetics, genomics and society: the 
responsibilities of scientists for science communication and education. Per. Med. 
9(6):633-643 (2012). 
13. Dodson C, van Riper M. Analysis of clinicians’ attitudes towards pharmacogenomics. 
Per. Med. 8(5): 533-540 (2011). 
 23 
14. Roederer M, van Riper M, Valgus J, Knafi G, McLeod H. Knowledge, attitudes and 
education of pharmacists regarding pharmacogenetic testing. Per. Med. 9(1): 19-27 
(2012). 
15. de Denus S, Letarte N, Hurlimann T, Lambert JP, Lavoie A, Robb L, Sheehan NL, 
Turgeon J, Vadnais B. An evaluation of pharmacists' expectations towards 
pharmacogenomics. Pharmacogenomics 14(2):165-175 (2013). 
16. Kricka LJ, Fortina P, Mai Y, Patrinos GP. Direct-access genetic testing: the view 
from Europe. Nat. Rev. Genet. 12(10):670 (2011). 
17. Howard HC, Borry P. Direct-to-consumer pharmacogenomic testing. 




Survey sample composition and demographic elements, as revealed by Section I of the 
questionnaires (see Supplementary Information). a: Questionnaires were given only to 
adult respondents with a minimum age of 18-years. b: Only 1 respondent indicated that 
they had studied in Italy. The remainder did not provide this information. c: Five 
respondents indicated that they had performed their post-graduate studies abroad, namely 
Italy , Germany and Sweden (1 respondent each), whereas 2 did not indicate the country 
in which they performed their post-graduate studies. 
 
 Pharmacists (n) Pharmacists (%) Physicians (n) Physicians (%) 
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Sample size 86 100 208 100 
Age (years) 
<35 a 31 36.1 72 34.6 
35-60 50 58.1 126 60.6 
>60 5 5.8 10 4.8 
Gender 
Male 48 55.8 120 57.7 
Female 38 44.2 88 42.2 
Place of study 
Greece 55 63.9 136 65.4 
Abroad 31 36.1 b 72 34.6 
Graduate studies 
Yes 12 13.9 c 80 38.5 






Main respondent group characteristics. Depiction of the most common medical 
specialties of the physicians who responded to our survey (A) and of the pharmacists’ 
professional experience (B). 
 
Figure 2 
Assessing the genetics knowledge of the respondent groups. A and B. Graphical 
representation indicating the pharmacists’ level of knowledge of genetics (Q16B) and 
pharmacogenomics and personalized medicine (Q17B), C. Comparative analysis of the 
self-assessed level of knowledge of physicians’ (Q12A) and pharmacists’ (Q17B) of 
pharmacogenomics and personalized medicine. D. Comparative analysis of undergraduate 
level of education of genetics and pharmacogenomics, based on the self-assessment of 
physicians (Q20A) and pharmacists (Q20B). 
 
Figure 3 
Evaluating pharmacists’ opinions and attitudes with respect to pharmacogenomics. 
A. Graphical display of the pharmacists’ attitudes to providing genetic analysis kits over the 
counter (Q22A), their awareness that the genetic analysis kits are considered a medical 
device (Q23B) and the recommendation for a pharmacogenomic test in certain drug labels 
(Q26B). B. Pharmacists’ opinions regarding the contribution of pharmacogenomics 
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towards reducing the occurrence and the overall frequency and severity of adverse drug 
reactions (Q31B), healthcare costs (Q33B) and costs of developing new drugs (Q32B).  
 
Figure 4 
Involvement with genetics, genetic testing and pharmacogenomics. A. Level of 
involvement of physicians and pharmacists with pharmacogenomics in their daily practice. 
B. Graphical display indicating whether physicians (Q13A) and pharmacists (Q24B) have 
advised their patients and clients, respectively, to undergo genetic and/or 
pharmacogenomic testing and reciprocally, whether physicians’ and pharmacists’ clients 
(Q14A and Q25B, respectively) had requested them to undertake genetic and/or 
pharmacogenomic testing. C. Assessment [GEORGE: self-assessment?] of as to whether 
physicians and pharmacists can provide sufficient information or explain the results of 
pharmacogenomic tests (Q16A and Q27B, respectively). 
 
Figure 5 
Professional opinion on ethical, legal, societal and regulatory issues pertaining to 
personalized medicine. A. Opinions from of physicians and pharmacists (Q19A and 
Q30B, respectively) as to whether an appropriate legal framework to cover genetic and 
pharmacogenomic testing exists in Greece. B. Opinions of physicians (Q17A) and 
pharmacists (Q28B) of direct-to-consumer genetic testing. C. Opinions of physicians 
(Q18A) and pharmacists (Q29B) regarding the reimbursement of expenses of 
pharmacogenomic testing by insurance companies. D. Opinions of physicians (Q11A) and 
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pharmacists (Q19B) in relation to whether the results of pharmacogenomic testing would 
positively affect patients’ medical care. 
 
Figure 6 
Assessing genetics knowledge in pharmacists. Graphical display of the correct answers 
of pharmacists in various questions pertaining to basic genetics (Q8B-Q11B) and 
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